Similar articles

• Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension.

  Baba T, Murabayashi S, Tomiyama T, Takebe K. Baba T, et al. Eur J Clin Pharmacol. 1990;38(3):305-7. doi: 10.1007/BF00315037. Eur J Clin Pharmacol. 1990. PMID: 2187701 Clinical Trial.
• Overview of clinical trials of dilevalol in essential hypertension.

  Glover DR, Tarbit WJ. Glover DR, et al. J Hum Hypertens. 1990 Jun;4 Suppl 2:49-53. J Hum Hypertens. 1990. PMID: 2142508
• Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.

  Chrisp P, Goa KL. Chrisp P, et al. Drugs. 1990 Feb;39(2):234-63. doi: 10.2165/00003495-199039020-00007. Drugs. 1990. PMID: 2184002 Review.
• Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations.

  Given BD, Perentesis G, Christopher JD, Herron J, Patrick JE, Kramer WG, Affrime MB. Given BD, et al. Am J Cardiol. 1989 Jun 5;63(19):12I-16I. doi: 10.1016/0002-9149(89)90122-7. Am J Cardiol. 1989. PMID: 2729123 Clinical Trial.
• Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.

  Lalonde RL, Tenero DM, Kazierad DJ. Lalonde RL, et al. Pharmacotherapy. 1990;10(1):15-28. Pharmacotherapy. 1990. PMID: 2179899 Review.